Telix Pharmaceuticals

Telix Pharmaceuticals Gross Margin

The Gross Margin of Telix Pharmaceuticals (TLX.AX) as of Nov 20, 2026 is 47.51 %. In the previous year, Gross Margin was 61.85 % — a change of -23.19% (lower).

Gross Margin

47.51 %

YoY

-23.19%

Last updated:

Gross Margin of Telix Pharmaceuticals is 2025 47.51 % . Gross Margin of Telix Pharmaceuticals was 2024 61.85 % . It decreases by -23.19% lower compared to the previous year.

Telix Pharmaceuticals's gross margin stands at 47.5%, down from 66.5% several years earlier.

The Telix Pharmaceuticals Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
27.03 USD
Jan 1, 2020
61.17 USD
Jan 1, 2021
66.46 USD
Jan 1, 2022
59.29 USD
Jan 1, 2023
61.05 USD
Jan 1, 2024
61.85 USD
Jan 1, 2025
47.51 USD
The Telix Pharmaceuticals Gross Margin history
YEARGross MarginYoY
47.51 %-23.19%
61.85 %+1.31%
61.05 %+2.96%
59.29 %-10.78%
66.46 %+8.63%
61.17 %+126.32%
27.03 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Telix Pharmaceuticals Stock analysis

What does Telix Pharmaceuticals do? Telix Pharmaceuticals Ltd. is a leading biopharmaceutical company specializing in the development of diagnostic and therapeutic solutions that work at the molecular level. The company's activities span across Europe, North America, and the Asia-Pacific region. Telix was formed through the merger of two Australian companies - Advanced Nuclear Medicine Ingredients (ANMI) and Radiopharmaceuticals Pty Ltd. The company's business model is based on translational medicine and it works closely with academic research groups and international partners to develop products and technologies aligned with the latest medical research and scientific knowledge. Telix has two main business divisions: Imaging and Therapy. The Imaging division focuses on the development of diagnostic radiopharmaceuticals for cancer and inflammation imaging, while the Therapy division concentrates on the development of radiopharmaceuticals for the treatment of cancer and other chronic diseases. The company offers a wide portfolio of products and solutions tailored to diseases of the nervous and immune systems, as well as to cancer diagnosis and treatment. These include the Prostate-Specific Membrane Antigen (PSMA)-targeting technology, which has the potential to significantly improve the early diagnosis and progression of prostate cancer, radiopharmaceuticals for bone imaging to enhance the diagnosis of bone metastases and other bone diseases, and radiopharmaceuticals for cancer therapy that show promising results in precision tumor treatment. Telix Pharmaceuticals aims to improve the diagnosis, treatment, and quality of life for patients with chronic diseases through its innovative products, strong network of partners, and commitment to entrepreneurial excellence. Telix Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Telix Pharmaceuticals stock

Gross Margin of Telix Pharmaceuticals is 47.51 % in 2025.

Gross Margin of Telix Pharmaceuticals changed from 61.85 % to 47.51 %, representing a -23.19% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Telix Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Telix Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Telix Pharmaceuticals

All Key Metrics — Telix Pharmaceuticals